JQDN

General

Jama Neurology-The Year In Review, 2024

Di: Stella

The latest JCR 2024 is released. Get access to the list of SCI Neurology journals by journal impact factor 2025. This narrative review evaluates the potential association between the adenovirus-vectored vaccines and neuroimmunological diseases, including Guillain-Barré syndrome, Bell JAMA Dermatology thrived in 2024. The editorial team evaluated a 15% increase in the number of article submissions in the past year (Table). A total of 1103 of 3182

JAMA Neurology Impact factor 2025

JAMA Network Open—The Year in Review, 2022 | Health Disparities | JAMA ...

Download Citation | On Mar 21, 2022, S. Andrew Josephson published JAMA Neurology —The Year in Review, 2021 | Find, read and cite all the research you need on ResearchGate

1. Hillis JM, Cliff ERS, Vokinger KN. AI Devices in Neurology-Moving From Diagnosis to Prognosis. JAMA Neurol. 2024. 2. Machado C. Response to Fischer et al. The This systematic review and meta-analysis examines the worldwide pathogen distribution and case Findings In fatality ratios of community-acquired bacterial meningitis from 1935 to 2022. For Authors | JAMA | JAMA Network .video-embed {margin: 2em 0;} For Authors About JAMA Why Publish in JAMA Instructions for Authors Submit Your Manuscript Author Reprints

Endovascular Stroke Thrombectomy for Patients With Large Ischemic Core: A Review JAMA Neurol. 2024 Oct 1;81 (10):1085-1093. doi: 10.1001/jamaneurol.2024.2500.

JAMA Neurology is an international peer-reviewed journal for physicians caring for people with neurologic disorders and those interested in the structure and function of the normal and

JAMA Neurology is an international peer-reviewed journal for physicians providing care for people with neurologic disorders. In this video, Editor Andrew Josephson, MD, reflects as our leader this 2023 Has been a busy year for JAMA Oncology and its editors. We have had the pleasure of receiving a substantial number of submissions and reviewing an exciting array of

Risk Factors for Young-Onset Dementia in the UK Biobank

  • List of Neurology journals by impact factor
  • Global Burden of Subarachnoid Hemorrhage
  • The current issue of JAMA Neurology
  • AI Devices in Neurology—Moving From Diagnosis to Prognosis

Read the current issue. Keep up to date with the latest research, clinical reviews, and opinions. The most widely read and highly cited peer-reviewed neurology journal Editorial July Online ahead of print 15, 2024 This Viewpoint examines the appropriateness of FDA accelerated approval of novel gene therapies to treat boys with Duchenne muscular dystrophy following clinical trials with

This cross-sectional study investigates the global burden of nontraumatic subarachnoid hemorrhage in 2021. This randomized clinical trial investigates whether first-line disease-modifying therapy can be safely discontinued in patients with long-term stable multiple sclerosis. Chicago, June 30, 2023 – JAMA and the journals in the JAMA Network are among the highest in their respective fields, according to the 2023 update to Clarivate’s annual Journal Citation

For JAMA Network Open, 2024 was a year of milestones. Our founding Editor in Chief, Fred Rivara, MD, MPH, stepped away after 7 years as our leader; this was after he DOI: 10.1001/jamaneurol.2024.0239 Corpus ID: 268511416 JAMA Neurology-The Year in Review, 2023. S. Josephson Published in JAMA Neurology 18 March 2024 Medicine This cohort study examines data from 3 single-center observational cohorts to test the capabilities of a commercially available plasma phosphorylated tau 217 immunoassay to

This cohort study of patients in Denmark with atrial fibrillation investigates whether discontinuation of oral anticoagulation is associated with an increased risk of recurrent Differential Diagnosis of Suspected Multiple Sclerosis in Pediatric and Late-Onset Populations: A Review JAMA Neurol. 2024 Sep 16. doi: 10.1001/jamaneurol.2024.3062. Online ahead of print.

  • January 1, 2024 Issue of JAMA Neurology
  • JOURNAL IMPACT FACTOR 120
  • SARS-CoV-2 Vaccination and Neuroimmunological Disease: A Review
  • JAMA Internal Medicine—The Year in Review, 2024

The Impact IF 2024 of JAMA Neurology is 9.82, which is computed in 2025 as per its definition. dysarthria dysphagia hypertonia decreased tendon JAMA Neurology IF is increased by a factor of 0.96 and approximate percentage

JAMA Neurology —The Year in Review, 2023 Author information 1 Editor, JAMA Neurology 2 Department of Neurology, Weill Institute for Neurosciences, University of California, San This narrative review evaluates the current and emerging landscapes of prognostic markers of neurologic recovery from disorders of consciousness caused by severe, acute brain Key Points Question Is the clinical phenotype of patients without dementia associated with blood phosphorylated tau 217 (p-tau 217) interpretation? Findings In this study

63.1 Journal Impact Factor of 63.1, among the top 5 journals in medicine and science This narrative review explores the current and future roles of chimeric antigen receptor (CAR) T-cell therapy in neurology, For Authors JAMA particularly for primary brain tumors and This unique concept and power of JAMA and the JAMA Network was shared in 2024 during visits by the Editors in Chief of JAMA, JAMA Oncology, and JAMA Ophthalmology

Explore the latest in epilepsy and seizures, including the epidemiology, etiology, diagnosis and management of seizure disorders.

A 31-year-old woman was seen with contractures in her fingers and toes, carpal inversion, dysarthria, dysphagia, hypertonia, decreased tendon reflexes, absence of Babinski sign, and JAMA Neurology-The Year in Review, 2023 JAMA Neurology-The Year in Review, 2023 more Creator Josephson, S Andrew more Is Part Of Archives of neurology (Chicago), 2024-05, This past year, 2024, brought many exciting practice-changing publications to JAMA Oncology across a wide variety of topics. Throughout the year, we published several

8. Hartung HP, Benedict RHB, Berger T, et al. Ocrelizumab in early-stage relapsing-remitting multiple sclerosis: the phase IIIb ENSEMBLE 4-year, single-arm, open-label This cohort study examines factors that are associated with the incidence of young-onset dementia among UK Biobank participants.